Gadgeel SM, et al. - Researchers assessed the combinations of platinum-doublet chemotherapy for advanced non—small-cell lung cancer (NSCLC) with the anti—programmed death 1 monocloncal antibody pembrolizumab in cohorts A-C of the multicohort phase 1/2 study KEYNOTE-021. Findings revealed that no dose-limiting toxicities occurred in any cohort at either pembrolizumab dose. It was noted that pembrolizumab in combination with carboplatin-paclitaxel and with pemetrexed-carboplatin offered encouraging antitumor activity and toxicity consistent with known toxicities of platinum-based chemotherapy or pembrolizumab monotherapy. Alopecia, fatigue, and nausea were the most frequent treatment-related adverse events (AEs).